PREFER presentation on patient preferences for Multiple Myeloma treatment wins ISPOR award


We are pleased to announce that Rosanne Janssens from KU Leuven won Best General Podium Research Presentation at ISPOR 2022, the annual conference for the Professional Society for Health Economics and Outcomes Research (ISPOR conference. The presentation was entitled PPreferences for Multiple Myeloma Treatment: A Stated Preference Survey Using Discrete Choice Experiment and Swing Weighting, presenting results from one of the PREFER project’s clinical patient preference case studies.

Rosanne Janssens has studied the implementation of discrete choice experiment and swing weighting as two preference elicitation methods. The aim was to establish which attributes of treatment matter most to multiple myeloma patients, and which trade-off between treatment characteristics they might be willing to make.

The study formed part of her PhD thesis. Now a Postdoctoral researcher in Pharmaceutical sciences at KU Leuven, Rosanne Janssens is continuing the legacy from PREFER. Seeing how patient preferences can help give patient a voice in medical product development by providing structured patient input to decision-making was one of the lessons learned from taking part in the PREFER project.

“I am looking forward to undertaking more preference research that puts patients both in the front and centre, as equal study partners”, says Rosanne Janssens.

Learn more about the Multiple Myeloma case study

About Rosanne Janssens

Rosanne Janssens defended her PhD thesis 20 October 2021 at KU Leuven. Focusing on patient preferences for cancer treatment, her PhD aimed at identifying multi-stakeholder challenges and solutions towards designing, conducting and using patient preference studies for informing drug development, regulatory and HTA decisions. Using qualitative and quantitative methods, her research elucidates: 1) stakeholder views on patient preference studies, 2) the impact of patient characteristics and methodological choices on measured preferences in preference studies and 3) how to use results from preference studies in drug decision-making.

By Josepine Fernow

Last modified: 2021-11-10